This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ariad Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Ariad Pharmaceuticals (ARIA)

Q2 2012 Earnings Call

August 02, 2012 8:30 am ET

Executives

Maria E. Cantor - Senior Vice President of Corporate Affairs

Harvey J. Berger - Principal Founder, Chairman of the Board, Chief Executive Officer, President and Chairman of Executive Committee

Edward M. Fitzgerald - Chief Financial Officer, Principal Accounting Officer, Executive Vice President and Treasurer

Analysts

Matthew Harrison - UBS Investment Bank, Research Division

Y. Katherine Xu - William Blair & Company L.L.C., Research Division

Ryan Martins - Lazard Capital Markets LLC, Research Division

Michael J. Yee - RBC Capital Markets, LLC, Research Division

Joel D. Sendek - Stifel, Nicolaus & Co., Inc., Research Division

Eileen Flowers - Jefferies & Company, Inc., Research Division

Ying Huang - Barclays Capital, Research Division

Michael G. King - Rodman & Renshaw, LLC, Research Division

Philip Nadeau - Cowen and Company, LLC, Research Division

Howard Liang - Leerink Swann LLC, Research Division

Karen E. Jay - JP Morgan Chase & Co, Research Division

Rachel L. McMinn - BofA Merrill Lynch, Research Division

Echo Yinghui He - Maxim Group LLC, Research Division

Presentation

Operator

Thank you for holding for ARIAD Pharmaceuticals Second Quarter 2012 Investor Conference Call. [Operator Instructions] Please be advised that this call is being taped at the company's request and will be archived on the company's website for 3 weeks from today. At this time, I'd like to introduce Ms. Maria Cantor, ARIAD's Senior Vice President, Corporate Affairs. Please go ahead.

Maria E. Cantor

Good morning, and thank you for joining us. This morning, we report on financial results and corporate developments for the second quarter of 2012. Dr. Harvey Berger, our Chairman and Chief Executive Officer; and Mr. Ed Fitzgerald, our Executive Vice President and Chief Financial Officer are joining me on this call.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs